ABOUT IJMMS

The International Journal of Medicine and Medical Sciences is published monthly (one volume per year) by Academic Journals.

The International Journal of Medicine and Medical Sciences (IJMMS) provides rapid publication (monthly) of articles in all areas of Medicine and Medical Sciences such as:

Clinical Medicine: Internal Medicine, Surgery, Clinical Cancer Research, Clinical Pharmacology, Dermatology, Gynaecology, Paediatrics, Neurology, Psychiatry, Otorhinolaryngology, Ophthalmology, Dentistry, Tropical Medicine, Biomedical Engineering, Clinical Cardiovascular Research, Clinical Endocrinology, Clinical Pathophysiology, Clinical Immunology and Immunopathology, Clinical Nutritional Research, Geriatrics and Sport Medicine

Basic Medical Sciences: Biochemistry, Molecular Biology, Cellular Biology, Cytology, Genetics, Embryology, Developmental Biology, Radiobiology, Experimental Microbiology, Biophysics, Structural Research, Neuropsychology and Brain Research, Cardiovascular Research, Endocrinology, Physiology, Medical Microbiology

Experimental Medicine: Experimental Cancer Research, Pathophysiology, Immunology, Immunopathology, Nutritional Research, Vitaminology and Ethiology

Preventive Medicine: Congenital Disorders, Mental Disorders, Psychosomatic Diseases, Addictive Diseases, Accidents, Cancer, Cardiovascular Diseases, Metabolic Disorders, Infectious Diseases, Diseases of Bones and Joints, Oral Preventive Medicine, Respiratory Diseases, Methods of Epidemiology and Other Preventive Medicine

Social Medicine: Group Medicine, Social Paediatrics, Medico-Social Problems of the Youth, Medico-Social Problems of the Elderly, Rehabilitation, Human Ecology, Environmental Toxicology, Dietetics, Occupational Medicine, Pharmacology, Ergonomy, Health Education, Public Health and Health Services and Medical Statistics

The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published approximately one month after acceptance. All articles published in IJMMS are peer-reviewed.

Submission of Manuscript

Submit manuscripts as e-mail attachment to the Editorial Office at: ijmms@academicjournals.org. A manuscript number will be mailed to the corresponding author.

The International Journal of Medicine and Medical Sciences will only accept manuscripts submitted as e-mail attachments.

Please read the Instructions for Authors before submitting your manuscript. The manuscript files should be given the last name of the first author.
Editors

Dr. J. Ibekwe
Acting Editor-in-chief,
International Journal of Medicine and Medical Sciences Academic Journals
E-mail: ijmms.journals@gmail.com
http://www.academicjournals.org/ijmms

Afrozul Haq
Editor, Laboratory Medicine
Department of Laboratory Medicine
Sheikh Khalifa Medical City
P.O. Box 51900, ABU DHABI
United Arab Emirates
Editorial Board

Chandrashekhar T. Sreeramareddy
Department of Community Medicine,
P O Box No 155, Deep Heights
Manipal College of Medical Sciences,
Pokhara,
Nepal

Professor Viroj Wiwanitkit
Wiwanitkit House, Bangkae,
Bangkok
Thailand 10160

Viroj Wiwanitkit
Department of Community Medicine,
P O Box No 155, Deep Heights
Manipal College of Medical Sciences,
Pokhara,
Nepal

Dr. Srinivas Koduru
Dept of Clinical Sciences
Collage of Health Sciences
University of Kentucky
Lexington USA

Sisira Hemananda Siribaddana
259, Temple Road, Thalapathpitiya,
Nugegoda, 10250
Sri Lanka

Weiping Zhang
Department of Oral Biology
Indiana University School of Dentistry
1121 West Michigan Street, DS 271
Indianapolis, IN 46202
USA

Dr. santi M. Mandal
Internal Medicine
UTMB, Galveston, TX,
USA

Konstantinos Tziomalos
Department of Clinical Biochemistry
(Vascular Prevention Clinic),
Royal Free Hospital Campus,
University College Medical School, University College
London, London,
United Kingdom

Sisira Hemananda Siribaddana
259, Temple Road, Thalapathpitiya,
Nugegoda, 10250
Sri Lanka

Weiping Zhang
Department of Oral Biology
Indiana University School of Dentistry
1121 West Michigan Street, DS 271
Indianapolis, IN 46202
USA

Lisheng XU
Ho Sin Hang Engineering Building
Department of Electronic Engineering
The Chinese University of Hong Kong
Shatin, N. T. Hong Kong,
China

Dr. santi M. Mandal
Internal Medicine
UTMB, Galveston, TX,
USA

Konstantinos Tziomalos
Department of Clinical Biochemistry
(Vascular Prevention Clinic),
Royal Free Hospital Campus,
University College Medical School, University College
London, London,
United Kingdom

Weiping Zhang
Department of Oral Biology
Indiana University School of Dentistry
1121 West Michigan Street, DS 271
Indianapolis, IN 46202
USA

Lisheng XU
Ho Sin Hang Engineering Building
Department of Electronic Engineering
The Chinese University of Hong Kong
Shatin, N. T. Hong Kong,
China

Dr. Mustafa Sahin
Department of Endocrinology and Metabolism
Baskent University,
Ankara,
Turkey

Mojtaba Salouti
School of Medical and Basic Sciences,
Islamic Azad University- Zanjan,
Iran

Dr. Mustafa Sahin
Department of Endocrinology and Metabolism
Baskent University,
Ankara,
Turkey

Cyril Chukwudi Dim
Department of Obstetrics & Gynaecology
University of Nigeria Teaching Hospital (UNTH)
P.M.B. 01129, Enugu. 400001,
Nigeria

Konstantinos Tziomalos
Department of Clinical Biochemistry
(Vascular Prevention Clinic),
Royal Free Hospital Campus,
University College Medical School, University College
London, London,
United Kingdom

Cyril Chukwudi Dim
Department of Obstetrics & Gynaecology
University of Nigeria Teaching Hospital (UNTH)
P.M.B. 01129, Enugu. 400001,
Nigeria

Mojtaba Salouti
School of Medical and Basic Sciences,
Islamic Azad University- Zanjan,
Iran

Imtiaz Ahmed Wani
Srinagar Kashmir, 190009,
India

Mojtaba Salouti
School of Medical and Basic Sciences,
Islamic Azad University- Zanjan,
Iran

Imtiaz Ahmed Wani
Srinagar Kashmir, 190009,
India
Electronic submission of manuscripts is strongly encouraged, provided that the text, tables, and figures are included in a single Microsoft Word file (preferably in Arial font).

The cover letter should include the corresponding author’s full address and telephone/fax numbers and should be in an e-mail message sent to the Editor, with the file, whose name should begin with the first author’s surname, as an attachment.

Article Types
Three types of manuscripts may be submitted:

Regular articles: These should describe new and carefully confirmed findings, and experimental procedures should be given in sufficient detail for others to verify the work. The length of a full paper should be the minimum required to describe and interpret the work clearly.

Short Communications: A Short Communication is suitable for recording the results of complete small investigations or giving details of new models or hypotheses, innovative methods, techniques or apparatus. The style of main sections need not conform to that of full-length papers. Short communications are 2 to 4 printed pages (about 6 to 12 manuscript pages) in length.

Reviews: Submissions of reviews and perspectives covering topics of current interest are welcome and encouraged. Reviews should be concise and no longer than 4-6 printed pages (about 12 to 18 manuscript pages). Reviews are also peer-reviewed.

Review Process
All manuscripts are reviewed by an editor and members of the Editorial Board or qualified outside reviewers. Authors cannot nominate reviewers. Only reviewers randomly selected from our database with specialization in the subject area will be contacted to evaluate the manuscripts. The process will be blind review.

Decisions will be made as rapidly as possible, and the journal strives to return reviewers’ comments to authors as fast as possible. The editorial board will re-review manuscripts that are accepted pending revision. It is the goal of the IJMMS to publish manuscripts within weeks after submission.

A list of non-standard Abbreviations should be added. In general, non-standard abbreviations should be used only when the full term is very long and used often. Each abbreviation should be spelled out and introduced in parentheses the first time it is used in the text. Only recommended SI units should be used. Authors should use the solidus presentation (mg/ml). Standard abbreviations (such as ATP and DNA) need not be defined.

The Introduction should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines.

Materials and methods should be complete enough to allow experiments to be reproduced. However, only truly new procedures should be described in detail; previously published procedures should be cited, and important modifications of published procedures should be mentioned briefly. Capitalize trade names and include the manufacturer’s name and address. Subheadings should be used. Methods in general use need not be described in detail.
**Results** should be presented with clarity and precision. The results should be written in the past tense when describing findings in the authors’ experiments. Previously published findings should be written in the present tense. Results should be explained, but largely without referring to the literature. Discussion, speculation and detailed interpretation of data should not be included in the Results but should be put into the Discussion section.

The **Discussion** should interpret the findings in view of the results obtained in this and in past studies on this topic. State the conclusions in a few sentences at the end of the paper. The Results and Discussion sections can include subheadings, and when appropriate, both sections can be combined.

The **Acknowledgments** of people, grants, funds, etc should be brief.

**Tables** should be kept to a minimum and be designed to be as simple as possible. Tables are to be typed double-spaced throughout, including headings and footnotes. Each table should be on a separate page, numbered consecutively in Arabic numerals and supplied with a heading and a legend. Tables should be self-explanatory without reference to the text. The details of the methods used in the experiments should preferably be described in the legend instead of in the text. The same data should not be presented in both table and graph form or repeated in the text.

**Figure legends** should be typed in numerical order on a separate sheet. Graphics should be prepared using applications capable of generating high resolution GIF, TIFF, JPEG or PowerPoint before pasting in the Microsoft Word manuscript file. Tables should be prepared in Microsoft Word. Use Arabic numerals to designate figures and upper case letters for their parts (Figure 1). Begin each legend with a title and include sufficient description so that the figure is understandable without reading the text of the manuscript. Information given in legends should not be repeated in the text.

**References:** In the text, a reference identified by means of an author’s name should be followed by the date of the reference in parentheses. When there are more than two authors, only the first author’s name should be mentioned, followed by ‘et al.’. In the event that an author cited has had two or more works published during the same year, the reference, both in the text and in the reference list, should be identified by a lower case letter like ‘a’ and ‘b’ after the date to distinguish the works.

**Examples:**

Nishimura (2000), Agindotan et al. (2003), (Kelebeni, 1983), (Usman and Smith, 2001), (Chege, 1998; Stein, 1987a,b; Tijani, 1993,1995) (Kumasi et al., 2001)

References should be listed at the end of the paper in alphabetical order. Articles in preparation or articles submitted for publication, unpublished observations, personal communications, etc. should not be included in the reference list but should only be mentioned in the article text (e.g., A. Kingori, University of Nairobi, Kenya, personal communication). Journal names are abbreviated according to Chemical Abstracts. Authors are fully responsible for the accuracy of the references.

**Examples:**


Case Studies

Case Studies include original case reports that will deepen the understanding of general medical knowledge.

The Title should be a brief phrase describing the contents of the paper. The Title Page should include the authors’ full names and affiliations, the name of the corresponding author along with phone, fax and E-mail information. Present addresses of authors should appear as a footnote.

The Abstract should be informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The Abstract should be 100 to 200 words in length. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Standard nomenclature should be used and abbreviations should be avoided. No literature should be cited. Following the abstract, about 3 to 10 key words that will provide indexing references should be listed.

A list of non-standard Abbreviations should be added. In general, non-standard abbreviations should be used only when the full term is very long and used often. Each abbreviation should be spelled out and introduced in parentheses the first time it is used in the text. Only recommended SI units should be used. Authors should use the solidus presentation (mg/ml).

The Introduction should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines. The presentation of the case study should include the important information regarding the case. This must include the medical history, demographics, symptoms, tests etc. Kindly note that all information that will lead to the identification of the particular patient(s) must be excluded.

The conclusion should highlight the contribution of the study and its relevance in general medical knowledge.

The Acknowledgments of people, grants, funds, etc should be brief. References: Same as in regular articles.

Short Communications

Short Communications are limited to a maximum of two figures and one table. They should present a complete study that is more limited in scope than is found in full-length papers. The items of manuscript preparation listed above apply to Short Communications with the following differences: (1) Abstracts are limited to 100 words; (2) instead of a separate Materials and Methods section, experimental procedures may be incorporated into Figure Legends and Table footnotes; (3) Results and Discussion should be combined into a single section.

Proofs and Reprints: Electronic proofs will be sent (e-mail attachment) to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript. With the exception of typographical or minor clerical errors, no changes will be made in the manuscript at the proof stage. Because IJMMS will be published freely online to attract a wide audience, authors will have free electronic access to the full text (in both HTML and PDF) of the article. Authors can freely download the PDF file from which they can print unlimited copies of their articles.

Copyright: Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, or thesis) that it is not under consideration for publication elsewhere; that if and when the Manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher.
ARTICLES

A theoretical study of Curcuma longa’s anticancer agents, curcumin I and curcumin II, in blood and gas by using density functional theory (DFT) and hartree–fock (HF)  
Faik Gökalp

Flowcytometric analysis of aldehyde dehydrogenase activity in mononuclear cells from umbilical cord blood  
Fadia M. Attia, Amani.A.El Baz, Mohamed abdou Abdel Naeim, Amany M. Hassan, Abdel Aziz M. Mohamed2 and Magdy A. El Barbary

Occurrence of hepatitis ‘B’ and ‘C’ amongst patients on antiretroviral drug therapy (ART) in a treatment centre in Calabar, Nigeria  
Inyang-Etoh P. C., Eyo G. O. and Philip-Ephraim E. E.
A theoretical study of *Curcuma longa*’s anticancer agents, curcumin I and curcumin II, in blood and gas by using density functional theory (DFT) and hartree–fock (HF)

Faik Gökalp

Ministry Of Education, Eskişehir, Turkey.

Received 4 March, 2014; Accepted 2 May, 2014

The active compounds of *Curcuma longa* (Curcumin I and Curcumin II) were investigated by using density functional theory (DFT) and hartree–fock (HF) in blood and gases. Curcumin II react with the radicalic forms of the molecules that cause cancer cell formation easily. On the other hand, the free energy of Curcumin I is higher than Curcumin II. Hence, hydrogen bonds formation of Curcumin II is more than Curcumin I. So, medical experimental studies can be done for these two substances.

**Key words:** Curcumin I, Curcumin II, density functional theory (DFT), hartree–fock (HF).

**INTRODUCTION**

*Curcuma longa*, a plant, is a member of the Zingiberaceae family. It grows in Asia, India, China and other countries with a tropical climate. It has long leaves and bears funnel-shaped yellow flowers. The rhizome is the part of the plant used medicinally; it is usually boiled, cleaned and dried, yielding a yellow powder. Dried *Curcuma longa* is the source of the spice turmeric, the ingredient that gives curry powder its characteristic yellow color. Turmeric is used extensively in foods for both its flavor and color. It has a long tradition of use in the Chinese as traditional medicine, particularly as an anti inflammatory agent and for the treatment of flatulence, jaundice, menstrual difficulties, hematuria, hemorrhage and colic. The active constituents of it are the flavonoid curcumin and volatile oils including tumorone, atlantone and zingiberone. Other constituents include sugars, proteins and resins (*Dobelis*, 1986; *Leung*, 1980).

Animal studies with rats and mice, as well as in human cell lines, have demonstrated curcumin’s ability to inhibit carcinogenesis at three stages: tumorpromotion, angiogenesis and tumor growth. In two studies of colon and prostate cancer, curcumin inhibited cell proliferation and tumor growth. Curcumin is also capable of suppressing the activity of several common mutagens and carcinogens in a variety of cell types in both *in vitro* and *in vivo* studies. The anti carcinogenic effects of it is due to direct antioxidant and free-radical scavenging effects, as well as its ability to indirectly increase glutathione levels, hepatic detoxification of mutagens and carcinogens, and inhibiting nitrosamine formation (*Limtrakul* et al., 1997; *Hanif* et al., 1997; *Dorai* et al., 2001; *Mehta* and *Moon*, 1991; *Soudamini* and *Kuttan*, 1989; *Azuine* and *Bhide*, 1992; *Pizorrno* and *Murray*, 1999).

Turmeric has been widely used for the treatment of some diseases. Epidemiological observations, though inconclusive, are suggestive that its consumption may...
reduce the risk of some form of cancers and render other protective biological effects in humans. These biological effects of it have been attributed to its constituent curcumin that has been widely studied for its anti-inflammatory, anti-angiogenic, anti-oxidant, wound healing and anti-cancer effects (Maheshwari et al., 2006).

Curcumin, one of the major components of turmeric, the dried rhizome of *Curcuma longa*, has been shown to have anti-proliferating and anti-carcinogenic properties. It has anti-tumor effects when curcumin (50 to 200 mg/kg) was orally administered to nude mice transplanted with the cancer cells (Cui et al., 2006). Curcumin exhibits growth inhibitory activity against prostate, colon and breast cancer. Although the effect of curcumin on ovarian cancer cells is not known, it is pointed that curcumin could induce cell death in ovarian cancer cells, and enhance apoptosis induced by tumor necrosis factor-related apoptosis (Wahl et al., 2007). Curcumin, the yellow pigment in turmeric is known to decrease proliferation of cancer cells by holding them at different phases of the cell cycle and to stimulate apoptosis in tumor cells. Curcumin encourages apoptosis primarily and contains the activation of caspase-3 and mitochondria-compromise pathway in sundry cancer cells of different tissue origin (Su et al., 2006). Curcumin, an active ingredient from the rhizome of the plant, has recently been demonstrated that the chemoprotective activities might be due to its ability to restrict cell growth and stimulate apoptosis (Shi et al., 2006). Curcumin is one of the most powerful chemoprotective and anticancer agents. Its biological effects range from antioxidant, anti-inflammatory to inhibition of angiogenesis and is also shown to possess specific antitumoral activity. The molecular mechanism of it has been demonstrated to have several targets and interacting macro-molecules within the cell (Singh and Khar, 2006).

Different dietary and pharmacological agents have been suggested as alternative strategies for treatment and obstruction of colorectal cancer. Curcumin, an active ingredient of turmeric, that inhibits growth of malignant tumours, has an important role in the obstruction and treatment of colorectal cancer (Reddy et al., 2006).

Curcumin, a component of turmeric (*C. longa*), is one such agent that has been shown to suppress the transcription factor nuclear factor-kappaB (NF-kappaB), which is implicated in proliferation, survival, angiogenesis and chemo-resistance (Kunnumakkara et al., 2007). Curcumin retains cell proliferation and alerts apoptosis in human leukaemia, prostate cancer and non-small cell lung cancer. It has a lot of pharmacological effects and has been pointed to have anti-inflammatory and anti-tumor activities (Balcerek and Matlawska, 2005). Preclinical studies in a variety of cancer cell lines containing breast, cervical, colon, gastric, hepatic, leukemia, oral epithelial, ovarian, pancreatic and prostate have everlastingly demonstrated that curcumin has anti-cancer activity *in vitro* and in preclinical animal models. Curcumin can be useful for the chemo-protection of colon cancer in humans (Johnson and Mukhtar, 2007).

MATERIALS AND METHODS

The thermodynamical properties of Curcumin I and Curcumin II are studied by using density functional theory (DFT) and hartree–fock (HF). RB3-LYP methods were used for geometry optimization. Calculation method comprising the DFT method was used. RB3-LYP and HF6-31G containing polarizing functions (d, p) basis set was used. These methods and fully optimized geometric structure of the compounds using the basic cluster was determined. Geometric structures were determined by calculating the frequency accuracy. The results obtained were evaluated. Gaussian 09 package program was used in the calculations.

RESULTS

The active compounds of *C. longa* (Curcumin I and Curcumin II)'s molecular structures are given in the Figures 1 and 2. The hyrogen bonds of Curcumin I and Curcumin II are given in the Figures 3 and 4. Hydrogen bond formations are shown on the molecular shapes of these two molecules in Figure 3 and 4. When we looked at the Gibbs free energy of Curcumin I and Curcumin II in blood by using DFT in Table 1, Curcumin I is higher than Curcumin II, since hydrogen bond formation in Curcumin...
II is more than Curcumin I. When we looked the Gibbs free energy of Curcumin I and Curcumin II in blood by using HF in Table 2, the results are parallel to those in Table 1; Curcumin I is higher than Curcumin II, since hydrogen bond formation in Curcumin II is more than Curcumin I. When we looked at the Gibbs free energy of Curcumin I and Curcumin II in gas by using DFT in Table 3, Curcumin I is higher than Curcumin II, since hydrogen bond formation in Curcumin II is more than Curcumin I.

**DISCUSSION**

When we looked at the Gibbs free energy of Curcumin I and Curcumin II in gas by using HF in Table 4, the results are parallel to the results in Table 3; Curcumin I is higher
than Curcumin II, since hydrogen bond formation in Curcumin II is more than Curcumin I. According to highest occupied molecular orbital-lowest unoccupied molecular orbital (HOMO-LUMO) differences in Tables 1 and 2, the difference between Curcumin I is -0.00522, 0.35706 and for Curcumin II is -0.00356, 0.35402. Curcumin I is more stable than Curcumin II. The dipole moments of Curcumin I and Curcumin II are 5.13480, 4.5055 and 11.8623, 9.0419. So, Curcumin II has higher dipole moment than Curcumin I. Curcumin II dissolves in blood easily than Curcumin I. In the gas form of these two substances, Curcumin I and Curcumin II, by using DFT and HF, the dipolar moment values are 6.1082, 5.2579 and 2.3726, 1.7572. They are near to each other. Therefore, we can assume that Curcumin II is eager to dissolve in blood and give reaction to radicalic forms of other molecules. Because of that, It slows cancer cells formation by preventing the radicalic damage. On the other hand, the free energy of Curcumin I is higher than Curcumin II. Hence, hydrogen bonds formation of Curcumin II is more than Curcumin I (5:3).

REFERENCES


Dobelis I (1986). Magic and Medicine of Plants. Pleasantville; Reader’s Digest Association, Inc.

| Table 1. The Curcumin I, Curcumin II values of $\Delta$G, HOMO, LUMO, $\Delta$ (HOMO-LUMO) and dipole moment in blood by using DFT. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| DFT (In blood) | $\Delta$G (Hartree) | HOMO | LUMO | $\Delta$ (HOMO-LUMO) | Dipole moment |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Curcumin I | -1263.366036 | -0.00476 | 0.00046 | -0.00522 | 5.13480 |
| Curcumin II | -1148.872154 | -0.00321 | 0.00035 | -0.00356 | 11.8623 |
| HOMO: highest occupied molecular orbital; LUMO: lowest unoccupied molecular orbital |

| Table 2. The Curcumin I, Curcumin II values of $\Delta$G, HOMO, LUMO, $\Delta$ (HOMO-LUMO) and dipole moment in blood by using HF. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| HF (in blood) | $\Delta$G (Hartree) | HOMO | LUMO | $\Delta$ (HOMO-LUMO) | Dipole moment |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Curcumin I | -1255.765819 | -0.30490 | 0.052 | 0.35706 | 4.5055 |
| Curcumin II | -1141.914713 | -0.30169 | 0.05233 | 0.35402 | 9.0419 |
| HOMO: highest occupied molecular orbital; LUMO: lowest unoccupied molecular orbital |

| Table 3. The Curcumin I, Curcumin II values of $\Delta$G, HOMO, LUMO, $\Delta$ (HOMO-LUMO) and Dipole Moment In Gas By Using DFT. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| DFT (in gas) | $\Delta$G (Hartree) | HOMO | LUMO | $\Delta$ (HOMO-LUMO) | Dipole moment |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Curcumin I | -1263.286962 | -0.00140 | 0.01354 | 0.13680 | 6.1082 |
| Curcumin II | -1148.798758 | -0.01391 | 0.00036 | 0.01427 | 2.3726 |
| HOMO: highest occupied molecular orbital; LUMO: lowest unoccupied molecular orbital |

| Table 4. The Curcumin I, Curcumin II values of $\Delta$G, HOMO, LUMO, $\Delta$ (HOMO-LUMO) and Dipole Moment In Gas By Using HF |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| HF (In Gas) | $\Delta$G (Hartree) | HOMO | LUMO | $\Delta$ (HOMO-LUMO) | Dipole moment |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Curcumin I | -1255.703083 | -0.29708 | 0.06246 | 0.35954 | 5.2579 |
| Curcumin II | -1141.858214 | -0.29072 | 0.06301 | 0.35373 | 1.7572 |
| HOMO: highest occupied molecular orbital; LUMO: lowest unoccupied molecular orbital |


Flowcytometric analysis of aldehyde dehydrogenase activity in mononuclear cells from umbilical cord blood

Fadia M. Attia¹, Amani.A.El Baz², Mohamed abdou Abdel Naeim², Amany M. Hassan¹, Abdel Aziz M. Mohamed² and Magdy A. El Barbary²

¹Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Egypt.
²Department of Physiology, Faculty of Medicine, Suez Canal University, Egypt.

Received 4 March, 2009; Accepted 5 May, 2014

Aldehyde dehydrogenase (ALDH) is a cytosolic enzyme that is responsible for the oxidation of intracellular aldehydes. Elevated levels of ALDH have been demonstrated in murine and human progenitor cells compared with other hematopoietic cells, and this is thought to be important in chemoresistance and purification techniques and an indication of the proper function of the cell. A Flowcytometric method for the assessment of ALDH activity in viable cells recently has been developed. Forty six cord blood samples from mothers which underwent normal delivery of full term infants were obtained, after informed consent. Mononuclear cells were obtained by Ficoll-Paque density centrifugation and ammonium chloride red cell lysis. Percentage of viable cells was determined by trypan blue exclusion dye. Cells were labeled with Aldefluor reagent (Vancouver Canada) as described by the manufacturer. Cells were then stained with phycoerythrin (PE)–conjugated anti-CD34 (Miltenyi Biotec, Cologne, Germany) antibodies for 30 min at 4°C. Cells were washed and re-suspended in phosphate-buffered saline (PBS) with 2% fetal calf serum. Cells were then analyzed on coulter epics flow cytometer. The mean percentage of ALDH enzyme expression among the CD34+ cells in the cord blood samples was 61.3% with a minimum of 28% and a maximum of 94.6%. Significant correlations were found between the white blood cell (WBCS) count in the cord blood samples and both the CD34+ cell count and the count of ALDH expressing cells, while no correlation was found between the CD34+ cells count or the ALDH expressing cells count in the cord blood samples and either the sex or the weight of the newborn. Identification and isolation of cells on the basis of ALDH activity provides a tool for their isolation and further analysis. In summary, a high ALDH-1 activity identifies CD34+ cells in cord blood.

Key words: Umbilical cord blood, stem cells, aldehyde dehydrogenase (ALDH), CD34.

INTRODUCTION

Aldehyde dehydrogenase (ALDH) is a family of enzymes involved in metabolism of aldehydes to their corresponding carboxylic acids (Cheung et al., 2007). It plays an important role in metabolism of vitamin A as well as in mechanisms of resistance to alkylating agents, for example cyclophosphamide (Storms et al., 1999). For these reasons, ALDH is considered a protecting or detoxifying enzyme, able to preserve stem cells from cytotoxic effects (Storms et al., 1999; Fallon et al., 2003; Hess et al., 2004). One of the accepted technologies to...
identify human hematopoietic stem cells (HSC) is based upon flow cytometry (FCM) detection of ALDH enzymatic activity (Storms et al., 1999).

The functional role of ALDH has been studied, with specific inhibitor of ALDH, diethylaminobenzaldehyde (DEAB), which was able to alter the molecular and cellular mechanisms that control self-renewal capacity of human HSC (Chute et al., 2006). The evidence of ALDH involvement in the physiology of HSC was further highlighted by a series of studies devoted to purification/analysis of highly immature progenitor cells, particularly in human cord blood (CB) as well as in murine bone marrow (BM) (Christ et al., 2007; Juopperi et al., 2007; Hess et al., 2006). The importance of ALDH in human hematopoiesis was also testified by a recent study in which the authors tried to purify HSCs by combining FCM cell sorting and Hoechst-33342 efflux ability (the so called "side population") (Pearce and Bonnet, 2007). At variance with previous findings obtained in mouse, human BM hematopoietic cells able to exclude Hoechst-33342 did not correspond to highly immature HSCs. On the other hand, the authors proposed that ALDH activity had to be considered as the reference method for the detection of immature HSCs in human BM, at the same time emphasizing the need for studies about expression pattern of ALDH in comparison with other hematopoietic cell markers in this tissue (Pearce and Bonnet, 2007).

Human HSCs have traditionally been characterized by the expression of cell surface markers such as CD34 (Civin et al., 1984; Bhatia et al., 1997a), but not all human hematopoietic repopulating cells express CD34 (Bhatia et al., 1998; Dao et al., 2003) and cell surface phenotype can be altered by cell cycle progression and ex vivo manipulation (Dorrell et al., 2000; Guenechea et al., 2000; Bhatia et al., 1997b; Hess et al., 2003; Nakamura et al., 1999; Sato et al., 1999). A purification strategy complementary to the use of surface phenotype involves the assessment of intracellular enzyme activities associated with the protection of primitive cells from oxidative insult during hematopoietic development. One promising purification strategy exploits cytosolic ALDH, an enzyme implicated in retinoid metabolism and the resistance of HSCs to alkylating agents such as cyclophosphamide (Sahovic et al., 1988; Takebe et al., 2001). Murine repopulating cells (Sharkis et al., 1997; Jones et al., 1995) and human hematopoietic progenitors have previously been isolated based on increased activity of intracellular ALDH (Storms et al., 1999; Jones et al., 1995).

One promising strategy is HSC isolation according to a conserved stem cell function rather than phenotype. In the murine system, lymphohematopoietic stem cells have been isolated according to the high expression of the detoxifying enzyme (ALDH) (Sharkis et al., 1997; Jones et al., 1995; Jones et al., 1995). Storms et al. (1999) described a fluorescent substrate of ALDH (termed aldefluor) that can be used to isolate cells with increased ALDH activity by fluorescence-activated cell sorting (FACS). The substrate is an amino acetaldehyde molecule conjugated to a BODIPY (4, 4-difluoro-5,7-dimethyl-4-bora-3a,4adiaza- 5-proprionic acid) fluorochrome that is metabolized by ALDH to an aminoacetate anion was retained within the cell because of its negative charge. Thus, the amount of fluorescent product that accumulates in viable cells correlates to ALDH activity and cells with high ALDH activity can be selected from human umbilical cord blood (UCB) or mobilized peripheral blood by FACS (Fallon et al., 2003; Storms et al., 1999). UCB cells isolated by using this strategy have demonstrated to be depleted of lineage committed hematopoietic cells and are enriched for primitive hematopoietic progenitors detected in clonogenic in vitro cultures (Storms et al., 1999). This approach has allowed the analysis of viable murine and human ALDH+ progenitors by flow cytometry (Storms et al., 1999).

MATERIALS AND METHODS

We obtained forty six cord blood samples from mothers attending Suez Canal University Hospital, after informed consent. All cord blood samples (each sample = 30 ml) were stored overnight at room temperature before ALDH analysis. The protocol was approved by the institutional research ethics committees. Mononuclear cells (MNCs) were obtained by Ficoll-Paque density centrifugation and 0.8% ammonium chloride red cell lysis. Percentage of viable cells was determined by trypan blue exclusion dye.

Cell labeling

Cells were labeled with Aldefluor reagent (Vancouver Canada) as described by the manufacturer. Cells were then stained with phycoerythrin (PE)–conjugated anti-CD34 (Miltenyi Biotec, Cologne, Germany) antibodies for 30 min at 4°C. Cells were washed and re-suspended in phosphate-buffered saline (PBS) with 2% fetal calf serum. Cells were then analyzed on couler epics flow cytometer. Aldefluor reagent was excited at 488 nm. Gates were set up to exclude nonviable cells and debris. The negative fraction was determined using appropriate isotype controls (Figures 1 and 2).

For consistent results, Aldefluor-stained cells must be analyzed within 2 h of labeling. However, cells retain their ability to convert the ALDH substrate for at least 24 h after collection. We stored cord blood samples overnight before Aldefluor labeling and analysis without any detectable effect on the ALDH profile. DEAB tubes or negative control tubes were done to confirm that cellular fluorescence was the result of the activity of cytosolic ALDH; cells were incubated with DEAB which is a specific, competitive inhibitor of cytosolic ALDH that is nontoxic to cells in vitro and in vivo for 15 min at 37°C. These steps were repeated for each sample to be tested.

Set-up analyzer

1. In set-up mode, a DEAB control sample was placed on the cytometer; on the FSC vs. SSC plot, the R1 region was adjusted to encompass the leukocyte population of interest based on scatter. 2. On the FL1 vs. SSC plot, the FL1 photo-multiplier tube (PMT)
Table 1. Count and percentage of CD34+ cells to the total leucocytic count (TLC) in the cord blood samples.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean</th>
<th>Maximum</th>
<th>Minimum</th>
<th>Standard deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of CD34+ cells to the TLC</td>
<td>3.60</td>
<td>8.10</td>
<td>1.40</td>
<td>1.40</td>
</tr>
<tr>
<td>Count of CD34+ cells × 10³/µl</td>
<td>0.48</td>
<td>1.12</td>
<td>0.12</td>
<td>0.23</td>
</tr>
</tbody>
</table>

TLC: thin layer chromatography.

Table 2. Count of ALDHbr cells × 10³/µl in cord blood samples.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean</th>
<th>Maximum</th>
<th>Minimum</th>
<th>Standard deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count of ALDHbr cells × 10³/µl</td>
<td>0.29</td>
<td>0.89</td>
<td>0.05</td>
<td>0.19</td>
</tr>
</tbody>
</table>

Table 3. Comparison between means of CD34+ cells count and ALDHbr cells count in cord blood samples.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean±SD</th>
<th>Range</th>
<th>Mean±SD</th>
<th>Range</th>
<th>t-test</th>
<th>Significance (2-tailed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD34+cells count × 10³/µl</td>
<td>0.12-1.16</td>
<td>0.49±0.23</td>
<td>0.05-0.89</td>
<td>0.29±0.23</td>
<td>14.07</td>
<td>0.000**</td>
</tr>
<tr>
<td>ALDHbr cells count × 10³/µl</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Difference is statistically significant.

RESULTS

The study population included 46 umbilical cord blood samples collected from immediate newborns, 22 males (47.8%) and 24 females (52.2%). The mean weight of the newborns was 3258.7 g, with a minimum of 2,300 g and a maximum of 3,900 g. The mean white blood cells count in the tested cord blood samples was 13.6 × 10³/µl, with a range of 5.7 × 10³/µl to 27.3 × 10³/µl, while the mean blood hemoglobin of the tested cord blood samples was 14.5 g/dl, with a range of 10.6 to 17.2 g/dl.

The mean percentage of the CD34 cells to the total leucocyte count was 3.6%; with a minimum of 1.4% and a maximum of 8.1% (Table 1); while the mean count of the CD34 cells × 10³/µl in cord blood samples was 0.48 × 10³/µl with a minimum of 0.12 and a maximum of 1.16 × 10³/µl (Table 1). The mean count of the cells expressing the ALDH enzyme × 10³/µl in cord blood samples was 0.29 × 10³/µl, with a minimum of 0.05 and a maximum of 0.89 × 10³/µl (Table 2). We found a statistically significant difference when we compared between the mean count of CD34+ cells and the mean count of ALDH expressing cells (Table 3). Also, there was a significant positive correlation between the count of CD34+ cells and the count of ALDH expressing cells (Figure 2). The mean percentage of ALDH enzyme expression among the CD34+ cells in the cord blood samples was 61.3% with a minimum of 28% and a maximum of 94.6% (Table 4 and Figure 3). Significant correlations were found between the WBCs count in the cord blood samples and both the

Data handling

1. FSC vs. SSC dot plot and region R1 that would encompass the leucocyte population of interest based on scatter were created.
2. Two FL1 vs. SSC dot plots were created gated on R1. A region R2 was created in both plots that began at the 2nd log decade of FL1 and was within the range of 200-400 on side scatter.
3. An ALDH positive sample data file was opened. The R1 region was adjusted in FSC vs. SSC dot plot to encompass the "viable" leucocyte population.
4. For data acquisition of test samples, the analyzer was put in acquisition mode and 100,000 events were collected on each ALDH and DEAB sample using the same instrument settings. DEAB control regions might need to be adjusted for each sample. ALDH-bright, SSC-low stem cells appeared in the R2 region.
5. For double expression of ALDH bright cells and CD34+ cells was done.

Statistical analysis

Statistical package for the social sciences (SPSS version 10.0) software was used for data analysis. The Student’s paired t-test for significance of no difference was used throughout this report.
Table 4. Percentage of ALDHbr cells to the CD34+ cells in cord blood samples.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean</th>
<th>Maximum</th>
<th>Minimum</th>
<th>Standard deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of ALDHbr cells to CD34+ cells</td>
<td>61.30</td>
<td>94.60</td>
<td>28</td>
<td>19.80</td>
</tr>
</tbody>
</table>

Figure 1. Percentage of ALDHbr cells to the CD34+ cells in cord blood samples

Figure 2. Correlation between WBCs count and CD34+ cells count. Pearson correlation: 0.557. Significance: 0.000; correlation is significant.

CD34+ cell count and the count of ALDH expressing cells (Figures 4 and 5). No correlation was found between the sexes or the weight of the newborn and neither the CD34+ cells count nor the ALDH expressing cells count in the cord blood samples.

DISCUSSION

Human cord blood hematopoietic cells with high ALDH activity are highly enriched for primitive CD34+ cells and depleted for lineage-positive (Lin+) cells (CD3, CD14, CD7, etc.).
CD20, and CD56), indicating that they do indeed represent a primitive hematopoietic cell population (Storms et al., 1999).

Methods to safely identify primitive HSCs with enhanced repopulating function are constantly sought for clinical stem cell transplantation. Conventionally, HSCs are purified using a single isolation strategy, such as the selection of cells based on cell surface phenotype (CD34 expression) or efflux of metabolic markers such as Hoechst dye by membrane pumps (Civin et al., 1984; Bhatia et al., 1997a; Sharkis et al., 1997; Gallacher et al., 2000; Guenechea et al., 2001; De Wynter et al., 1998; Goodell et al., 1997; Handgretinger et al., 2003). However, cell phenotype, such as CD34 surface expression, can vary depending on micro-environmental factors or cellular activation (Dao et al., 2003; Hess et al., 2003) and clinical procedures are incompatible with the use of toxic or DNA-intercalating dyes. Nontoxic cell-sorting strategies based on conserved stem cell function, rather than to merely identify a stem cell antigen (Morita et al., 2003).

In the current study, only 61.3 ± 19.8% of CD34+ cells were found to express ALDH activity. Robert et al. (1999) found that 74% ± 20 of CD34+ cells express ALDH activity, while David et al. (2004) found that the percentage was 91 ± 1.4%. Christ et al. (2003) found that the percentage was 95 ± 1%. These data strongly suggest that there is functional heterogeneity within the CD34+ cell population and that further purification of human stem or progenitor cells may be achieved through the analysis of ALDH activity. ALDHbr UCB cells was found to be 2% of the thin layered chromatography (TLC) while it was about 1% in the studies done by Christ et al. (2003) and David et al. (2004).

In the current study, no relation could be found between sex or weight of the newborn and expression of ALDH or CD34+. It was reported that birth weight of the neonate did not affect the mono-nucleated cell count (MNC) and subsequently CD34+ cell count. Hiett et al.
(1995) reported that there was no significant difference in the mean number of progenitors/UCB unit according to newborn weight. On contrary to these results, Arovita et al. (2005) reported that the correlation between birth weight and CD34+ cell concentration was statistically clearly significant. In this study, they tested 1368 CB samples for associations of selected factors as birth weight. Another study included 3838 CB units analyzing CD34+ cell contents only on units with a volume > 80 ml, a correlation analysis of CD34+ count and weight, revealing that baby weight was associated with higher CD34+ cell content in UCB (P = 0.0001). In this same study, a correlation analysis of CD34+ count and sex revealed that male newborns was associated with higher content of CD34+ cells (P = 0) (Guenechea et al., 2000).

Arovita et al. (2005) reported also that male infants had significantly higher median CD34+ cell concentration than female infants (31.8 \times 103/\mu l vs. 30.2 \times 103/\mu l, respectively (P = 0.03). There are several potential applications to this strategy for identifying and isolating HSCs. Enumerating ALDHbr cells may be a more reliable means for quantitating the transplantable stem cells in bone marrow, peripheral blood and UCB. Isolating ALDHbr cells also may be an effective method for purging autologous bone marrow or peripheral blood stem cell collections of tumor cells (Colvin et al., 1999). According to the manufacturers, the Aldefluor kit is active against the ALDH-1 isofrom but not the ALDH-3 isofrom. Both ALDH1 and ALDH3 are reportedly involved in chemoresistance (Civin et al., 1984; Bhatia et al., 1998; Bhatia et al., 1997b). In this study, we confirmed the use of the ALDH substrate kit to identify cord blood stem/progenitor cells expressing CD 34 via multicolor flow cytometry of cord blood ALDH+ cells.

A study done by Schuurhuis et al. (2013) showed marked difference between ALDH activity of HSC and LSC with the AML BM indicating the importance of ALDH activity as a functional stem cell biomarker and its usefulness in identification and purification of HSC and LSC with the aim of treatment decision making, relapse prediction and development of LSC specific therapies. Although HSC and LSC can, in a considerable part of AML cases, be distinguished using aberrancies of marker expression (van Rhenen et al., 2007a; van Rhenen et al., 2007b; Jordan et al., 2000) and scatter properties (Terwijn et al., 2007; Janssen et al., 2011), assessment of ALDH activity enables such discrimination in all AML cases even in the absence of aberrancies.

ALDH has received considerable attention as a functional marker for identification of cells with enhanced tumorigenic/metastatic potential and elevated therapeutic resistance in several cancers of epithelial origin (Ginestier et al., 2007; Jiang et al., 2009; Tanei et al., 2009). A possible application of ALDH detection by FCM to the field of acute leukemia may derive from the study of Cheung et al. (2007), in which the authors described ALDH expression in AML. They noted that in AML patients in complete remission, a relevant population of cells characterized by high ALDH activity remained (Cheung et al., 2007). So their data about multidimensional expression profile of ALDH combined with other hematopoietic antigens in normal BM precursors could represent the basis to distinguish by FCM leukemic from normal ALDH+ cells.

Overall, the ALDH kit is quick (1 h in total), easy to use and does not significantly affect cell viability or repopulation ability. The fluorescent substrate may be analyzed in conjunction with other common fluorochromes on a standard benchtop flow cytometer equipped with a 488 nm laser line. These properties suggest that this is a technique more suitable for the clinic than alternative techniques that are toxic and require expensive analytical equipment (for example, a UV laser) (Goodell et al., 1997).

REFERENCES


Occurrence of hepatitis ‘B’ and ‘C’ amongst patients on antiretroviral drug therapy (ART) in a treatment centre in Calabar, Nigeria

Inyang-Etoh P. C.1*, Eyo G. O.1 and Philip-Ephraim E. E.2

1Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, College of Medical Sciences, University of Calabar, Calabar, Rivers State, Nigeria.
2Department of Internal Medicine, Faculty of Clinical Sciences, College of Medical Sciences, University of Calabar, Calabar, Rivers State, Nigeria.

Received 4 March, 2014; Accepted 15 May, 2014

The occurrence of hepatitis ‘B’ and ‘C’ virus amongst patients on antiretroviral drug therapy (ART) was studied. Two hundred (200) human immunodeficiency virus (HIV) positive subjects on ART and 100 apparently healthy HIV negative subjects (control) were recruited for the study. The subjects aged 1 to 75 years were screened for hepatitis B and C viral antibodies using hepatitis B and C test strips manufactured by ACON Laboratories. Questionnaire were also administered. CD4 counts of the subjects were determined using CyFlow Counter manufactured by GEM Laboratories, Germany. Fourteen (7%) of the subjects were positive for hepatitis B virus (HBV) infection, 6 (3%) for hepatitis C virus (HCV) and 2 (1%) for mixed infections. In the control group, a prevalence of 6 (6%) was recorded for HBV, 4 (4%) for HCV and none for mixed infections. Among the test group, subjects in age group 51 to 60 years had the highest prevalence rate for HBV (25%), 31 to 40 years for both HCV (7.3%) and mixed infection (3.6%). There was no statistically significant difference in infection according to age P=0.475. Males had a higher prevalence rate (9.1%) than the females (5.4%) for HBV, but there was no statistically significant difference in HBV infections according to gender P=0.404. In HCV infection, males had a higher prevalence rate (5.7%) than females (0.9%), but there was no statistically significant difference in HCV infection according to gender P=0.089. Subjects with CD4 counts in the range of 1401 to 1600 had the highest infection rate (50%) for HBV and 201 to 400 for HCV (7.7%) and mixed infection (5.1%). This work has shown that HBV and HCV are common among patients on ART and the need for routine screening of this category of patients in order to aid in the effective management of co-infections.

Key words: Hepatitis B, Hepatitis C, antiretroviral therapy, HIV, Calabar.

INTRODUCTION

In Nigeria and other developing countries, human immunodeficiency virus/acquired immunodeficiency virus (HIV/AIDS) disease is a major public health problem, and a serious threat to development. Since the introduction of potent antiretroviral drug therapy (ART), HIV/AIDS has been successfully converted from a uniformly fatal illness
to a manageable chronic infection. Correspondingly, during the past years, the opportunistic infections that complicate profound immunosuppression have been replaced with newer forms of morbidity and even mortality. Chief among these has been the development of progressive liver disease due to hepatitis C virus (HCV) and hepatitis B virus (HBV). Due to their shared routes of transmission, HCV and HBV are frequently found in the HIV-infected host, while HCV co-infection has deservedly gained considerable attention as a major cause of mortality in the post-highly active antiretroviral therapy era (Bonacini et al., 2001). Complications of HBV-related liver disease are being increasingly recognized especially as drug-resistant forms of HBV have become nearly universal (Saravanan et al., 2007).

HBV and HCV co-infection in HIV positive individuals is of utmost importance due to the underlying consequences such as the hepatological problems associated with these viruses, which have been shown to decrease the life expectancy in the HIV-infected patients (Koziel and Peters, 2007; Major, 2009). Moreover, among the HIV-infected patients, 2 to 4 million are estimated to have chronic HBV co-infection, while 4 to 5 million are co-infected with HCV (Soriano et al., 2009). In Nigeria, the average carrier rate of hepatitis B in the general population is estimated to be 4% (Taylor et al., 2006). This study was an attempt to investigate the current prevalence of HBV and HCV among patients on ART in the study centre.

MATERIALS AND METHODS

Study location

The study centre was ART Laboratory, General Hospital, Calabar located in Calabar Municipality in Cross River State. Cross River is a coastal state in South Eastern Nigeria, bordering Cameroon to the east and it is located in Nigeria’s Delta region.

Patients’ recruitment

The study subjects were 200 consecutive patients aged 1 to 75 years on ART, while 100 HIV negative apparently healthy control subjects who were randomly selected from members of the general hospital community whose HIV status were negative at the time of study. The study subjects and the controls were age and sex matched. The study was conducted between November 2011 and June 2012. Questionnaires were administered to obtain the demographic data of the subjects. Ethical clearance was sought and obtained from the State Ministry of Health. Prior to specimen collection, verbal consent from each of the subjects and/or their guardians were sought and obtained. Those who declined participation were excluded from the study.

CD4 T lymphocytes count

Partec CyFlow Counter was the machine used for analysis of CD4 count with serial No. 090746022 manufactured by GEM Laboratories, a biotechnological company in Germany (Pantec GmbH Am flugplatz 13 D-02828 Glorilitz Germany).

The Partec CyFlow Counter which is a fully equipped portable/mobile flow cytometry system (FCM) was used for the identification and the enumeration of the CD4 T lymphocytes which is the first point of attack of the HIV virus.

HBV screening test

Sample from each subject was screened serologically for hepatitis B surface antigen. The test was done using ACON hepatitis B surface antigen rapid test strip manufactured by ACON Laboratory Inc 4108 Serrette Valley Boulevard, San Diego, CA 92121 in United States of America.

The HBsAg one step hepatitis B surface antigen test strip (serum/plasma) is a qualitative, lateral flow immunoassay for the detection of HBsAg in serum or plasma. The membrane is pre-coated with anti-HBsAg antibodies on the test line region of the strip. During testing, the serum or plasma specimen reacts with the particle coated with anti-HBsAg antibody. The mixture migrates upward on the membrane chromatographically by capillary action to react with anti-HBsAg antibodies on the membrane and generate a colour line. The presence of this coloured line in the test region indicates a positive result, while its absence indicates a negative result. This test strip has been compared with a leading commercial HBsAg EIA test and the correlation between this two is over 90%. The relative sensitivity, specificity and accuracy are 99, 97 and 98.5%, respectively (Blumberg et al., 1971).

HCV screening test

Hepatitis C virus antibodies was screened using ACON one strip hepatitis C virus test strip manufactured by ACON Laboratory Inc 4108 Serrette Valley Boulevard, San Diego, CA 92121 in United States of America. This HCV one step hepatitis C test strip (serum/plasma) is a qualitative, membrane based immunoassay for the detection of antibody to HCV in serum or plasma. The membrane is coated with recombinant HCV antigen on the test line region of the strip. During testing, the serum or plasma specimen reacts with the protein A coated particles. The mixture migrates upward on the membrane chromatographically by capillary action to react with recombinant HCV antigen on the membrane and generate a coloured line. The presence of this coloured line indicates a positive result, while its absence indicates a negative result. To serve as a procedural control, a coloured line will always appear at the controlled line region indicating that proper volume of specimen has been added and membrane wicking has occurred. This test strip has been compared with a leading commercial HCV EIA test. The relative sensitivity, specificity and accuracy are >99.0, 98.6 and 99.3%, respectively (van der Poel et al., 1991; Wilber, 1993).

HIV screening test

HIV screening was done using the serial algorithm of screening with determined and confirmed result with UniGold (WHO, 1993). Alere determined HIV1/2 is an immunochromatographical test for the qualitative detection of antibodies to HIV-1 and HIV-2.

HIV confirmatory test using uni-gold

All the test samples that were positive were confirmed with a second test using uni-gold. For testing, two drops of whole blood from the pricked finger were allowed to fall into the sample port, followed by two drops of wash buffer and allowed to react.
Table 1. Prevalence of HBV and HCV amongst subjects examined according to age.

<table>
<thead>
<tr>
<th>Age group</th>
<th>No. examined</th>
<th>Test subject</th>
<th>Control subject</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%) with HBV infection</td>
<td>No. (%) with HCV infection</td>
<td>No. (%) with both infections</td>
</tr>
<tr>
<td>1-10</td>
<td>6</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>11-20</td>
<td>7</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>21-30</td>
<td>58</td>
<td>2 (3.45)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>31-40</td>
<td>55</td>
<td>5 (9.1)</td>
<td>4 (7.3)</td>
</tr>
<tr>
<td>41-50</td>
<td>57</td>
<td>4 (7.0)</td>
<td>2 (3.5)</td>
</tr>
<tr>
<td>51-60</td>
<td>8</td>
<td>2 (25)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>61-70</td>
<td>8</td>
<td>1 (12.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>71 above</td>
<td>1</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Total</td>
<td>200</td>
<td>14 (7)</td>
<td>6 (3)</td>
</tr>
</tbody>
</table>

Table 2. Prevalence of infection among subject examined according to gender.

<table>
<thead>
<tr>
<th>Gender</th>
<th>No. examined</th>
<th>Test subject</th>
<th>Control subject</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%) with HBV infection</td>
<td>No. (%) with HCV infection</td>
<td>No. (%) with both infections</td>
</tr>
<tr>
<td>Female</td>
<td>112</td>
<td>6 (5.4)</td>
<td>1 (0.9)</td>
</tr>
<tr>
<td>Male</td>
<td>88</td>
<td>8 (9.1)</td>
<td>5 (5.7)</td>
</tr>
<tr>
<td>Total</td>
<td>200</td>
<td>14 (7)</td>
<td>6 (3)</td>
</tr>
</tbody>
</table>

Antibodies of HIV-1 or HIV-2 proteins were bound to the colloidal gold linked antigens. The antibody protein colloidal gold complex moves chromatographically along the membrane to the test and control regions of the test device. A positive reaction is visualised by a pink band in the test region of the device and in the control line. A negative reaction occurs in the absence of human immunoglobulin antibodies to HIV in the analysed specimen. Consequently, no visually detectable band develops in the test region of the device.

Data analysis

Variables were analysed using Statistical Package for Social Sciences (SPSS) software.

RESULTS

Two hundred (200) HIV positive subjects on ART and 100 apparently healthy HIV negative subjects (control) were recruited into the study.

Table 1 shows the prevalence of HBV and HCV amongst subjects examined according to age. In the test subjects group, those in the age group 51 to 60 years had the highest prevalence rate of infection with HBV (25%), but there was no statistically significant difference in the prevalence of HBV infection by age ($\chi^2 = 6.9$, df (7), $P > 0.05$). Those in age group 31 to 40 years had the highest HCV rate infection (7.3%). But there was no statistically significant difference in HCV infection by age ($\chi^2 = 6.2$, df (7), $P > 0.05$).

Amongst those with mixed infection, subjects in age group 31 to 40 years had the highest prevalence of infection (3.6%), but there was no statistically significant difference in mixed infection ($\chi^2 = 5.3260$, df (7), $P > 0.05$). Among the control subjects, age group of 51 to 60 years had the highest infection with HBV and HCV (12.5 and 12.5%), respectively. There was no statistically significant difference in infection according to age ($\chi^2 = 1.813$, df (7), $P > 0.05$), but there was no statistically significant difference between males and females ($\chi^2 = 0.404$, df (1), $P = 0.864$). In the control subjects, females were more infected (5.7%) than males (3.6%) and there was no statistically significant difference in mixed infection according gender ($\chi^2 = 3.884$, df (1), $P > 0.05$).
(8.7%) with HBV than males (3.7%), but there was no statistically significant difference in infection according to gender ($\chi^2 = 1.098$, df (1), $P = 1.410$), while males were more infected (5.6%) with HCV than females (2.2%), but there was also no significant difference in the infection ($\chi^2 = 0.740$, df (1), $P > 0.05$).

Table 3 shows the distribution of infection according to CD4 count. Subjects with a CD4 count of 1401 to 1600, had the highest infection rate (50%) with HBV. In HCV infection, the CD4 count of 201 to 400 had the highest prevalence rate of infection (7.7%). In the control group, subjects with CD4 count of 601 to 800 had the highest infection rate (12.5%) with HBV.

Among those with HCV infection, subjects with CD4 count of 401 to 600 had the highest infection rate (9.1%). No mixed infection was recorded in the control group.

### DISCUSSION

From the results obtained from the test subjects, those in age group 51 to 60 years had the highest prevalence rate of infection for HBV (25%). This can be compared to the work done by Denue et al. (2011) at medical wards of University of Maiduguri Teaching Hospital, Nigeria on the survey of hepatitis B and C virus prevalence in HIV positive patients, who had a prevalence rate of 12.3% for HBV and 0.5% HCV infection with no mixed infection obtained. Similarly, this work can be compared to the work done by Adewole et al. (2009) at the Department of Medicine, Obafemi Awolowo University, Ile-Ife, Nigeria, on hepatitis B and C virus co-infection in Nigeria patients with HIV infection. Adewole et al. (2009) had 11.5% prevalence rate for HBV, 2.3% prevalence rate for HCV and 1.5% for mixed infections. This result can also be compared with the work carried out by Soriano et al. (2009) on hepatitis B and C in HIV/AIDS, Hong Kong, who had 23% for HBV, 16% for HCV and 5 to 10% mixed infections. Those in age group 31 to 40 years had the highest prevalence rate with HCV infection (7.3%). Among those with mixed infection, subjects in age group 31 to 40 years had the highest prevalence of infection (3.6%), but there was no statistically significant difference in mixed infection ($P > 0.05$). Among the control subjects, age group of 51 to 60 years had the highest prevalence with HBV and HCV (12.5 and 12.5%), respectively. There was no mixed infection in the control subjects.

The prevalence of HBV and HCV infection according to gender showed that in HBV infection males (9.1%) were more infected than females (5.4%), but there was no statistically significant differences between infections in males and females ($P > 0.05$). Among those with mixed infection, females were more infected (8.9%) than males (5.7%) and there was a statistically significant difference in mixed infection according to gender $P < 0.05$. In the control subjects, female were more infected with HBV (8.7%) than males (3.7%), but there was no statistically significant difference in infection according to gender $P > 0.05$. This can be compared to the work done by Denue et al. (2011), where blood donors were used as their controls, with a percentage prevalence of 5.2% for HBV and 1.4% for HCV. The distribution of CD4 count showed that CD4 count group of 1401 to 1600 had the highest infection rate (50%) with HBV. In HCV infection, the CD4 count group of 201 to 400 has the highest prevalence rate of infection (7.7%). In the control group, those with CD4 count of 601 to 800 CD4 group had the highest infection with HBV (12.5%). Among those with HCV infection subjects in CD4 count group of 401 to 600 had the highest infection rate (9.1%). No mixed infection was recorded in the control group. This can also be compared with the work done by Denue et al. (2011) at medical wards of University of Maiduguri, Nigeria on the survey of

### Table 3. Distribution of infection according to CD4 count of subject examined.

<table>
<thead>
<tr>
<th>CD4 count range</th>
<th>Test subject</th>
<th>Control subject</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%) with HBV</td>
<td>No. (%) with HCV</td>
</tr>
<tr>
<td>0-200</td>
<td>2 (9.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>201-400</td>
<td>4 (10.2)</td>
<td>3 (7.7)</td>
</tr>
<tr>
<td>401-600</td>
<td>3 (6.4)</td>
<td>1 (2.0)</td>
</tr>
<tr>
<td>601-800</td>
<td>3 (9.4)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>801-1000</td>
<td>1 (5.3)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>1001-1200</td>
<td>0 (0)</td>
<td>1 (7.1)</td>
</tr>
<tr>
<td>1201-1400</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>1401-1600</td>
<td>1 (50)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>1601-1800</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Total</td>
<td>200</td>
<td>14 (7)</td>
</tr>
</tbody>
</table>
hepatitis B and C virus prevalence in HIV positive patients. The mean CD4 count of the control group was significantly higher (181 cell/µl) than the test subjects (117 cell/µl).

According to WHO estimates, the global burden of HIV, HBV and HCV is 33.2, 400 and 170 million, respectively. Knowledge of the prevalence and distribution of blood borne viruses and sexually transmitted disease (STDs) in different part of the world, and particularly in Africa it is important for the planning of prevention measures and the development of vaccination programmes. More females than males were presented for care during the study period, but majority of males in the control subjects were blood donors. The gender inequality in presentation for therapy is consistent with the sex distribution documented in majority of treatment centres, particularly in the first decade of ART. The reason for more females at the study centre is that women present for care after positive HIV test on their sick children, death of their husbands or perhaps they are more sensitive to changes in their health and may be socially conditioned to seek and receive assistance for their sickness. This however does not mean that more women are infected with HIV in study centre, as study in Nigeria actually found that more men were afflicted with HIV/AIDS (Ola et al., 2005).

HIV has been shown conclusively to be an independent risk factor for more rapid CD4 decline, although it has been associated with increased occurrence of HBV, but HCV has not been known to decline CD4 count. The limitation of this study has been the availability funds for serotyping of these viruses, that is, confirmation of HBV and HCV, respectively. This work has shown that HBV and HCV are common amongst patients on ART. It is therefore advisable to screen for these viruses in all the HIV infected individuals and their sexual partners as a routine management and check up in order to aid in the proper management of the disease.

REFERENCES


